TSPAN8 and COVID-19: The conserved role of TSPAN8 for all SARS-CoV-2 VOCs imply that TSPAN8 is an attractive therapeutic target to limit COVID-19, which we explored with a TSPAN8-blocking antibody approach developed in the oncology field (Bonnet et al., 2019; Kim et al., 2015).